Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Macular Degeneration
Interventions
bevasiranib, ranibizumab
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
Enrolling by invitation No phase listed Observational

Implementation of the NEDS EyeCTester App

NCT04607369
Conditions
Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
Interventions
EyeCTester
Device
Lead sponsor
Neuro-Eye Diagnostic Systems, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bellaire, Texas
Conditions
Macular Degeneration
Interventions
BI 754132
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Age-related Macular Degeneration
Interventions
CNTO 2476, iTrack Model 275 micro catheter
Biological · Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Arcadia, California • Philadelphia, Pennsylvania
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Conditions
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Interventions
700 ug dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Abilene, Texas
Conditions
Choroid Neovascularization, Age-Related Macular Degeneration
Interventions
AGN 211745, Ranibizumab 500µg
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Proteomics Testing In Chronic Atrophy

NCT07298291
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
AC Tap (anterior chamber paracenthesis)
Procedure
Lead sponsor
ClinOmicsAI
Network
Eligibility
50 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Erie, Pennsylvania
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neovascular Age-related Macular Degeneration
Interventions
SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • Arcadia, California • Campbell, California + 25 more
Conditions
Dry Age Related Macular Degeneration
Interventions
Copaxone Injection
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Age-Related Macular Degeneration
Interventions
0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions
AIV007
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
Conditions
Low Vision, Neovascular Age-related Macular Degeneration
Interventions
Vision rehabilitation
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 105 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665
Conditions
Stargardt Disease
Interventions
Emixustat, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
16 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more
Completed No phase listed Observational Accepts healthy volunteers

CEI Van Outreach Screening Study

NCT01510392
Conditions
Glaucoma, Macular Disease, Keratoconus
Interventions
OCT imaging, the FDA Cleared iVue
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Geographic Atrophy
Interventions
Sham, Lampalizumab
Other · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda PBM treatment, Valeda Sham treatment
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 8 more
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more